









Markets
/
Stocks
/
nasdaq-absi
/

Absci Corp

ABSI

2.730USD

-0.050-1.80%

Market hours （ET）Quotes delayed by 15 min

246.72MMarket Cap

LossP/E TTM



Absci Corp

2.730

-0.050-1.80%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Absci Corp

Currency: USD Updated: 2026-03-27

Key Insights

Absci Corp's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 127 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.87.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Absci Corp's Score

Industry at a Glance

Industry Ranking

127 / 391

Overall Ranking

246 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Absci Corp Highlights

StrengthsRisks

Absci Corporation is a clinical-stage biopharmaceutical company advancing therapeutics with generative design. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. It has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.80M.

Fairly Valued

The company’s latest PE is -3.30, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 99.31M shares, increasing 0.03% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 7.21K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.61.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

8.029

Target Price

+178.77%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Absci Corp is 5.70, ranking 330 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 650.00K, representing a year-over-year decrease of 2.26%, while its net profit experienced a year-over-year decrease of 2.00%.

Score

Industry at a Glance

Previous score

5.70

Change



Financials

5.92

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.51

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.84

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.13

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Absci Corp's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Absci Corp is 5.92, ranking 350 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.30, which is -69.97% below the recent high of -0.99 and -88.50% above the recent low of -6.22.

Score

Industry at a Glance

Previous score

5.92

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 127/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Absci Corp is 8.00, ranking 163 out of 391 in the Biotechnology & Medical Research industry. The average price target is 9.00, with a high of 10.00 and a low of 5.80.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

8.029

Target Price

+178.77%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Absci Corp

ABSI

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Absci Corp is 7.46, ranking 46 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.24 and the support level at 2.28, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.96

Change

-1.5

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.065

Buy

RSI(14)

49.911

Neutral

STOCH(KDJ)(9,3,3)

50.402

Sell

ATR(14)

0.234

High Vlolatility

CCI(14)

18.675

Neutral

Williams %R

43.750

Buy

TRIX(12,20)

0.340

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

2.904

Sell

MA10

2.895

Sell

MA20

2.707

Buy

MA50

2.774

Sell

MA100

3.087

Sell

MA200

3.084

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Absci Corp is 5.00, ranking 136 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 64.99%, representing a quarter-over-quarter decrease of 0.69%. The largest institutional shareholder is Catherine Wood, holding a total of 12.55M shares, representing 8.35% of shares outstanding, with 2.81% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

22.08M

+15.42%

ARK Investment Management LLC

Star Investors

12.16M

+21.07%

BlackRock Institutional Trust Company, N.A.

9.62M

+29.18%

McClain (Sean)

8.70M

-0.27%

Redmile Group, LLC

8.25M

The Vanguard Group, Inc.

Star Investors

7.28M

+12.87%

State Street Investment Management (US)

2.06M

+14.52%

Phoenix Ventures Partners II LP.

4.75M

-49.28%

Geode Capital Management, L.L.C.

3.05M

+24.84%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Absci Corp is 3.27, ranking 154 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 2.06. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.